# reload+after+2024-01-21 16:45:05.529059
address1§1900 Lake Park Drive
address2§Suite 380
city§Smyrna
state§GA
zip§30080
country§United States
phone§678 384 7220
fax§678 384 7281
website§https://www.geovax.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
fullTimeEmployees§14
companyOfficers§[{'maxAge': 1, 'name': 'Mr. David Alan Dodd', 'age': 73, 'title': 'Chairman, President & CEO', 'yearBorn': 1950, 'fiscalYear': 2023, 'totalPay': 384200, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mark J. Newman Ph.D.', 'age': 68, 'title': 'Chief Scientific Officer', 'yearBorn': 1955, 'fiscalYear': 2023, 'totalPay': 291500, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Kelly T. McKee Jr., M.D., M.P.H.', 'age': 73, 'title': 'Chief Medical Officer', 'yearBorn': 1950, 'fiscalYear': 2023, 'totalPay': 361034, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Harriet Latham Robinson Ph.D.', 'age': 85, 'title': 'Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board', 'yearBorn': 1938, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark W. Reynolds CPA', 'age': 61, 'title': 'CFO & Corporate Secretary', 'yearBorn': 1962, 'fiscalYear': 2023, 'totalPay': 348200, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Jeffrey  Welch', 'title': 'Head of Process Development & Manufacturing Operations', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. John W. Sharkey Ph.D.', 'age': 67, 'title': 'Vice President of Business Development', 'yearBorn': 1956, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.892
priceToSalesTrailing12Months§Infinity
currency§USD
dateShortInterest§1702598400
forwardEps§-0.87
exchange§NCM
quoteType§EQUITY
shortName§GeoVax Labs, Inc.
longName§GeoVax Labs, Inc.
firstTradeDateEpochUtc§1601040600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c7c31a63-264a-3189-a2f8-87643849f80c
gmtOffSetMilliseconds§-18000000
targetHighPrice§8.0
targetLowPrice§4.0
targetMeanPrice§6.0
targetMedianPrice§6.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§1.792
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
